Aliases & Classifications for Mammographic Density

MalaCards integrated aliases for Mammographic Density:

Name: Mammographic Density 57 72

External Ids:

OMIM 57 607308
UMLS 72 C1846502

Summaries for Mammographic Density

MalaCards based summary : Mammographic Density is related to insulin-like growth factor i and ductal carcinoma in situ. An important gene associated with Mammographic Density is IGF1 (Insulin Like Growth Factor 1), and among its related pathways/superpathways are Cytochrome P450 - arranged by substrate type and Signaling by ERBB4. The drugs Ethanol and Ergocalciferol have been mentioned in the context of this disorder. Affiliated tissues include breast, testes and bone, and related phenotypes are homeostasis/metabolism and endocrine/exocrine gland

Wikipedia : 75 Breast cancer screening is the medical screening of asymptomatic, apparently healthy women for breast... more...

More information from OMIM: 607308

Related Diseases for Mammographic Density

Diseases related to Mammographic Density via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 162)
# Related Disease Score Top Affiliating Genes
1 insulin-like growth factor i 30.6 PRL IGFBP3 IGF1 ESR1
2 ductal carcinoma in situ 30.4 PGR ESR1 CYP19A1
3 hypothyroidism 29.8 PRL IGFBP3 IGF1
4 female breast cancer 29.4 PGR ESR1 CYP1A1
5 endometriosis 29.1 PGR HSD17B1 ESR1 CYP19A1
6 breast cancer 27.2 PRL PGR IGFBP3 IGF1 ESR1 CYP1B1
7 breast disease 27.0 PRL PGR IGFBP3 IGF1 ESR1 CYP1B1
8 slipped capital femoral epiphysis 10.6 IGFBP3 IGF1
9 secondary adrenal insufficiency 10.6 IGFBP3 IGF1
10 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 10.6 IGFBP3 IGF1
11 diffuse idiopathic skeletal hyperostosis 10.6 IGFBP3 IGF1
12 pituitary infarct 10.6 PRL IGF1
13 galactorrhea 10.6 PRL IGF1
14 pseudohypoparathyroidism, type ia 10.6 PRL IGF1
15 marasmus 10.6 IGFBP3 IGF1
16 schizophreniform disorder 10.6 PRL COMT
17 body mass index quantitative trait locus 1 10.5
18 empty sella syndrome 10.5 PRL IGF1
19 sheehan syndrome 10.5 PRL IGF1
20 acid-labile subunit deficiency 10.5 IGFBP3 IGF1
21 isolated growth hormone deficiency, type ib 10.5 IGFBP3 IGF1
22 in situ carcinoma 10.5
23 fetal macrosomia 10.5 IGFBP3 IGF1
24 traumatic brain injury 10.4 IGF1 COMT
25 osteoporosis, juvenile 10.4 IGFBP3 IGF1
26 testicular leydig cell tumor 10.4 ESR1 CYP17A1
27 pseudovaginal perineoscrotal hypospadias 10.3 IGFBP3 CYP17A1
28 bartholin's gland adenoma 10.3 PGR ESR1
29 vestibular gland benign neoplasm 10.3 PGR ESR1
30 lung leiomyoma 10.3 PGR ESR1
31 fibromyalgia 10.3 PRL IGF1 COMT
32 vulvar syringoma 10.3 PGR ESR1
33 glassy cell carcinoma of the cervix 10.3 PGR ESR1
34 vulvar leiomyoma 10.3 PGR ESR1
35 trigonitis 10.3 PGR ESR1
36 vulvar benign neoplasm 10.3 PGR ESR1
37 predominantly cortical thymoma 10.3 PGR ESR1
38 breast scirrhous carcinoma 10.3 PGR ESR1
39 breast medullary carcinoma 10.3 PGR ESR1
40 oncocytic breast carcinoma 10.3 PGR ESR1
41 bartholin's gland benign neoplasm 10.3 PGR ESR1
42 endometrial disease 10.3 ESR1 CYP19A1
43 cribriform carcinoma 10.3 PGR ESR1
44 endometrial squamous cell carcinoma 10.3 PGR ESR1
45 hyperpituitarism 10.3 PRL IGFBP3 IGF1
46 postpartum depression 10.3 PRL ESR1 COMT
47 progesterone resistance 10.3 PGR ESR1
48 pituitary adenoma 1, multiple types 10.3 PRL IGFBP3 IGF1
49 apocrine adenocarcinoma 10.3 PGR ESR1
50 adenoid basal cell carcinoma 10.3 PGR ESR1

Graphical network of the top 20 diseases related to Mammographic Density:



Diseases related to Mammographic Density

Symptoms & Phenotypes for Mammographic Density

Clinical features from OMIM:

607308

MGI Mouse Phenotypes related to Mammographic Density:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.14 COMT CYP17A1 CYP19A1 CYP1A1 CYP1B1 ESR1
2 endocrine/exocrine gland MP:0005379 10.09 COMT CYP19A1 CYP1A1 ESR1 HSD17B1 IGF1
3 behavior/neurological MP:0005386 10.08 COMT CYP17A1 CYP19A1 ESR1 HSD17B1 IGFBP3
4 cardiovascular system MP:0005385 9.93 COMT CYP19A1 CYP1A1 ESR1 IGF1 PGR
5 adipose tissue MP:0005375 9.89 CYP17A1 CYP19A1 ESR1 IGF1 IGFBP3
6 integument MP:0010771 9.85 CYP19A1 ESR1 IGF1 IGFBP3 PGR PRL
7 liver/biliary system MP:0005370 9.72 CYP19A1 CYP1A1 ESR1 IGFBP3 PRL
8 neoplasm MP:0002006 9.65 CYP1B1 ESR1 IGF1 PGR PRL
9 reproductive system MP:0005389 9.56 COMT CYP17A1 CYP19A1 ESR1 HSD17B1 IGF1
10 renal/urinary system MP:0005367 9.46 COMT CYP19A1 ESR1 IGF1
11 skeleton MP:0005390 9.1 CYP17A1 CYP19A1 ESR1 IGF1 IGFBP3 PGR

Drugs & Therapeutics for Mammographic Density

Drugs for Mammographic Density (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 122)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 2, Phase 3 64-17-5 702
2
Ergocalciferol Approved, Nutraceutical Phase 3 50-14-6 5280793
3
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
4
2-Phenylethanol Experimental Phase 2, Phase 3 60-12-8 6054
5 Bone Density Conservation Agents Phase 3
6 Micronutrients Phase 3
7 Trace Elements Phase 3
8 Ergocalciferols Phase 3
9 Nutrients Phase 3
10 Vitamin D2 Phase 3
11 Calciferol Phase 3
12 Olive Phase 2, Phase 3
13 Antioxidants Phase 2, Phase 3
14 3,4-dihydroxyphenylethanol Phase 2, Phase 3
15 Disinfectants Phase 2, Phase 3
16 Anti-Infective Agents, Local Phase 2, Phase 3
17 Protective Agents Phase 2, Phase 3
18 Platelet Aggregation Inhibitors Phase 2, Phase 3
19 Anti-Infective Agents Phase 2, Phase 3
20
Atorvastatin Approved Phase 2 134523-00-5 60823
21
Metformin Approved Phase 2 657-24-9 4091 14219
22
Letrozole Approved, Investigational Phase 2 112809-51-5 3902
23
Exemestane Approved, Investigational Phase 2 107868-30-4 60198
24
Calcium carbonate Approved, Investigational Phase 2 471-34-1
25
Lovastatin Approved, Investigational Phase 2 75330-75-5 53232
26
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
27
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
28
Calcium Approved, Nutraceutical Phase 2 7440-70-2 271
29
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 2 83-88-5 493570
30
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
31
Epicatechin Investigational Phase 2 35323-91-2, 490-46-0 72276
32
Epigallocatechin gallate Investigational Phase 2 989-51-5 65064
33
Epigallocatechin Experimental, Investigational Phase 2 970-74-1 72277
34
Afimoxifene Investigational Phase 2 68392-35-8
35 Hormones Phase 2
36 Hypoglycemic Agents Phase 2
37 Steroid Synthesis Inhibitors Phase 2
38 Aromatase Inhibitors Phase 2
39 Catechol Phase 2
40 Tea Phase 2
41 Antacids Phase 2
42 Gastrointestinal Agents Phase 2
43 Anti-Ulcer Agents Phase 2
44 Hydroxytamoxifen Phase 2
45 Estrogens Phase 2
46 Hormone Antagonists Phase 2
47 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
48 Selective Estrogen Receptor Modulators Phase 2
49 Antineoplastic Agents, Hormonal Phase 2
50 Estrogen Receptor Modulators Phase 2

Interventional clinical trials:

(show top 50) (show all 56)
# Name Status NCT ID Phase Drugs
1 Breast Cancer Screening With MRI in Women Aged 50-75 Years With Extremely Dense Breast Tissue: the DENSE Trial Active, not recruiting NCT01315015 Phase 4
2 Vitamin D and Breast Cancer Biomarkers Completed NCT01224678 Phase 3
3 An Explanatory Clinical Trial of Breast Cancer Prevention Completed NCT00148057 Phase 3
4 A Pilot Study of Hydroxytyrosol, a Component of Olive Oil for Breast Cancer Prevention In Women At High Risk Of Breast Cancer Recruiting NCT02068092 Phase 2, Phase 3 Hydroxytyrosol
5 Statins and Breast Cancer Biomarkers Unknown status NCT00914017 Phase 2 Atorvastatin;Placebo
6 Phase II, Randomized,Double-blind, Placebo-controlled, Study of the Efficacy of Green Tea Extract on Biomarkers of Breast Cancer Risk in High Risk Women With Differing Catechol-O-methyl Transferase (COMT) Genotypes Completed NCT00917735 Phase 2 Green tea extract supplement
7 Phase II Randomized Study of Neoadjuvant Metformin Plus Letrozole vs Placebo Plus Letrozole for ER-positive Postmenopausal Breast Cancer Completed NCT01589367 Phase 2 Metformin;Placebo
8 Cancer Risk and Biomarkers of Tamoxifen Chemoprevention Completed NCT00295100 Phase 2 Tamoxifen
9 A Study to Identify Biomarker Modulation by a Cyclooxygenase-2 (COX-2) Inhibitor in Breast Tissue of Premenopausal Women at High Risk for Estrogen Receptor Negative (ERN) Breast Cancer Completed NCT00056082 Phase 2 celecoxib
10 A Trial of Exemestane in Postmenopausal Women With DCIS or at High Risk for Invasive Breast Cancer Completed NCT00073073 Phase 2 Exemestane
11 A Randomized, Double-Blind, Placebo-Controlled Study of 4-hydroxytamoxifen Topical Gel in Women With Mammographically Dense Breast Recruiting NCT03063619 Phase 2 Afimoxifene
12 A Randomised, Double Blinded, Six-armed Placebo Controlled Study to Investigate Optimal Dose of Tamoxifen With the Most Favourable Side Effect Spectre and With Mammography Density Reduction Non-inferior to That of 20 mg Tamoxifen (Karisma 2) Active, not recruiting NCT03346200 Phase 2 Tamoxifen Oral Tablet;Placebo Oral Tablet
13 Mammographic Density and Soy Isoflavones Active, not recruiting NCT00204490 Phase 2
14 A Phase 2 Trial of Lovastatin for Modification of Abnormal Breast Duct Cytology and Risk-Associated Biomarkers in Women at High Inherited Risk of Breast Cancer Terminated NCT00285857 Phase 2 Lovastatin
15 Randomized Placebo-Controlled Biomarker Modulation Trial Using Celecoxib in Premenopausal Women at High Risk for Breast Cancer Terminated NCT00088972 Phase 2 celecoxib
16 A Single-Centre Pilot Trial Investigating the Efficacy and Safety of Enobosarm and Anastrozole in Pre-menopausal Women With High Mammographic Breast Density Completed NCT03264651 Phase 1 enobosarm
17 A Single Dose Trial to Evaluate the Pharmacokinetics of Testosterone and Anastrozole From Subcutaneous Testosterone and Anastrozole (T+Ai) in Premenopausal Women Completed NCT03314298 Phase 1 testosterone anastrozole
18 RANKL Inhibition and Breast Tissue Biomarkers in Premenopausal Women With Dense Breasts Completed NCT03629717 Phase 1 Denosumab;Calcium;Vitamin D
19 Pilot Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer Completed NCT00976339 Phase 1 Cholecalciferol
20 Phase IB Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women With a History of Hormone Receptor-Negative Breast Cancer Completed NCT00516243 Phase 1 defined green tea catechin extract
21 A Phase I Trial of the Safety and Immunogenicity of a DNA Plasmid Based Vaccine (WOKVAC) Encoding Epitopes Derived From Three Breast Cancer Antigens (IGFBP-2, HER2, and IGF-1R) in Patients With Breast Cancer Recruiting NCT02780401 Phase 1
22 Change in Mammographic Density With Metformin Use: A Companion Study to NCIC Study MA.32 Unknown status NCT01666171 metformin hydrochloride
23 THE EFFECTS OF VITAMIN D ON MAMMOGRAPHIC DENSITY AND BREAST TISSUE Unknown status NCT02239874
24 The British Breast Cancer Study - National Cancer Research Network Cohort (BBC-NCRN) Unknown status NCT00896818
25 Total Xonoestrogen Body Burden in Relation to Mammographic Density, a Marker of Breast Cancer Risk Completed NCT00839696
26 Pilot Study to Examine Histological Characteristics of Mammographic Density With Molecular Breast Imaging: Part 2 - Premenopausal Women Completed NCT01588834
27 Mammographic Density and the Risk of Tumor Recurrence in Asian Women: a Case-control Study Completed NCT02771665
28 KEEPS Mammographic Density And Breast Health Ancillary Study Completed NCT02524561 CEE pill;Estradiol patch;Active Progesterone
29 Genetics of Mammographic Appearances and Patterns (The GenMap Study) Completed NCT01160510
30 The Effects of Adjuvant Zoladex Plus Tamoxifen on Breast Density in Pre- or Peri-menopausal Women With Early-stage Breast Cancer Completed NCT00827307 tamoxifen;Goserelin
31 Transillumination for Breast Cancer Risk Assessment Completed NCT00188721
32 Alberta Physical Activity and Breast Cancer Prevention (ALPHA) Trial Completed NCT00522262
33 Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer Completed NCT01097278
34 Pilot Trial to Identify and Characterize Breast Stem Cells in Women at Average Risk and Increased Risk for Breast Cancer Completed NCT00923377
35 The Ultrasound Study of Tamoxifen Completed NCT01582074
36 The Effect of Aspirin on Mammogram Density (TEAM) Completed NCT00470561 Aspirin;Placebo
37 Modulation of Breast Cancer Risk Biomarkers by High Dose Vitamin D Completed NCT01166763 vitamin D3
38 Combination of Low Dose Antiestrogens With Omega-3 Fatty Acids for Prevention of Hormone-independent Breast Cancer Completed NCT00723398 Raloxifene 60 Mg Oral Tablet;Raloxifene 30 Mg Oral Tablet;Lovaza 4gm & Raloxifene 30mg
39 A Randomized Study Of The Effect Of Exemestane (Aromasin) Versus Placebo On Breast Density In Postmenopausal Women At Increased Risk For Development Of Breast Cancer Completed NCT00066586 exemestane;Placebo
40 Evaluation of Changes in Mammographic Breast Density Associated With Bazedoxifene, Raloxifene, and Placebo in Postmenopausal Women: An Ancillary Study of Protocol 3068A1-301-WW Completed NCT00418236
41 Exercise Diet and Sex Hormones in Postmenopausal Women (NEW) Completed NCT00470119
42 Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Menstrual Cycle Pilot Study Completed NCT00006425
43 Improving Cancer-Related Outcomes in Shift Workers Completed NCT02609373
44 Breast Cancer and Insulin Resistance: Implications for Preventive Counseling in Familial and Sporadic Cases Completed NCT00304941
45 Breast Imaging Screening Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-up Study Completed NCT00006421
46 A Study of Breast Cancer, Breast Disease, Mammographic Density and Pesticides Among a Population From Triana, Alabama Completed NCT00341315
47 Longitudinal Changes in Mammographic Density and Risk of Breast Cancer Recruiting NCT00445445
48 Association Between Maternal Metabolic Disturbances During the First Pregnancy and Breast Density Recruiting NCT03920098
49 Breast Radiology Evaluation and Study of Tissues (Breast) Stamp Project Active, not recruiting NCT00475761
50 Soy Treatment for High-risk Women Active, not recruiting NCT01219075

Search NIH Clinical Center for Mammographic Density

Genetic Tests for Mammographic Density

Anatomical Context for Mammographic Density

MalaCards organs/tissues related to Mammographic Density:

41
Breast, Testes, Bone, Liver, Skin, Thyroid, Pituitary

Publications for Mammographic Density

Articles related to Mammographic Density:

(show top 50) (show all 1113)
# Title Authors PMID Year
1
Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. 38 8
26073781 2015
2
Common variants in ZNF365 are associated with both mammographic density and breast cancer risk. 38 8
21278746 2011
3
Heritability of mammographic density, a risk factor for breast cancer. 38 8
12239257 2002
4
Genome-wide association study of peripheral blood DNA methylation and conventional mammographic density measures. 38
30694562 2019
5
Quantification of breast tissue density: Correlation between single-sided portable NMR and micro-CT measurements. 38
31176808 2019
6
Transverse relaxation-based assessment of mammographic density and breast tissue composition by single-sided portable NMR. 38
31034648 2019
7
A review of the influence of mammographic density on breast cancer clinical and pathological phenotype. 38
31177342 2019
8
Associations between mammographic density and tumor characteristics in Chinese women with breast cancer. 38
31254158 2019
9
Circulating lipids, mammographic density, and risk of breast cancer in the Nurses' Health Study and Nurses' Health Study II. 38
31264139 2019
10
Mammographic densities of Aboriginal and non-Aboriginal women living in Australia's Northern Territory. 38
30941443 2019
11
Calibrated Breast Density Measurements. 38
30545682 2019
12
BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. 38
30643217 2019
13
Effects of drospirenone and norethisterone acetate combined with estradiol on mammographic density and proliferation of breast epithelial cells-A prospective randomized trial. 38
31239112 2019
14
Changes in mammographic density over time and the risk of breast cancer: An observational cohort study. 38
31132476 2019
15
Association between alcohol consumption and mammographic density: a hospital-based cross-sectional study. 38
30680689 2019
16
The association between mammographic density and breast cancer risk in Western Australian Aboriginal women. 38
30977028 2019
17
The relationship between terminal duct lobular unit features and mammographic density among Chinese breast cancer patients. 38
30561789 2019
18
Mammographic Density Change and Risk of Breast Cancer. 38
31298705 2019
19
Relationship of circulating insulin-like growth factor-I and binding proteins 1-7 with mammographic density among women undergoing image-guided diagnostic breast biopsy. 38
31337427 2019
20
Obesity-Associated Extracellular Matrix Remodeling Promotes a Macrophage Phenotype Similar to Tumor-Associated Macrophages. 38
31323189 2019
21
Breast cancer pathology and stage are better predicted by risk stratification models that include mammographic density and common genetic variants. 38
30941651 2019
22
Are mammographic density phenotypes associated with breast cancer treatment response and clinical outcomes? A systematic review and meta-analysis. 38
31352313 2019
23
Prediction of reader estimates of mammographic density using convolutional neural networks. 38
30746393 2019
24
Impact of Background Parenchymal Enhancement on Diagnostic Performance in Screening Breast MRI. 38
31327575 2019
25
Performance of Screening Breast MRI across Women with Different Elevated Breast Cancer Risk Indications. 38
31063080 2019
26
A Deep Learning Mammography-based Model for Improved Breast Cancer Risk Prediction. 38
31063083 2019
27
A new automated method to evaluate 2D mammographic breast density according to BI-RADS® Atlas Fifth Edition recommendations. 38
30770972 2019
28
Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of Vitamin D Supplementation in Premenopausal Women at High Risk for Breast Cancer (SWOG S0812). 38
31138522 2019
29
Reproductive Factors and Mammographic Density: Associations Among 24,840 Women and Comparison of Studies Using Digitized Film-Screen Mammography and Full-Field Digital Mammography. 38
30865217 2019
30
Annual versus biennial screening: diagnostic accuracy among concurrent cohorts within the Ontario Breast Screening Program. 38
31233138 2019
31
A case-control evaluation of 143 single nucleotide polymorphisms for breast cancer risk stratification with classical factors and mammographic density. 38
31251818 2019
32
A Case-Control Study to Add Volumetric or Clinical Mammographic Density into the Tyrer-Cuzick Breast Cancer Risk Model. 38
31423486 2019
33
Changes in mammographic density following bariatric surgery. 38
31076368 2019
34
Validation of the breast cancer surveillance consortium model of breast cancer risk. 38
30796654 2019
35
A Longitudinal Study of the Association between Mammographic Density and Gene Expression in Normal Breast Tissue. 38
30613869 2019
36
Predictors of mammographic density among women with a strong family history of breast cancer. 38
31242899 2019
37
The Relationship of Breast Density and Positive Lumpectomy Margins. 38
30888516 2019
38
"A Natural Progression": Australian Women's Attitudes About an Individualized Breast Screening Model. 38
31003994 2019
39
Joint association of mammographic density adjusted for age and body mass index and polygenic risk score with breast cancer risk. 38
31118087 2019
40
Molecular and cellular basis of mammary gland fibrosis and cancer risk. 38
30450584 2019
41
Serum 25-hydroxyvitamin D and mammographic density in premenopausal Spanish women. 38
30836177 2019
42
Differences between screen-detected and interval breast cancers among BRCA mutation carriers. 38
30673971 2019
43
Prediction of Cancer Masking in Screening Mammography Using Density and Textural Features. 38
30100155 2019
44
Early-life Growth and Benign Breast Disease. 38
31107507 2019
45
Adolescent caffeine consumption and mammographic breast density in premenopausal women. 38
31152213 2019
46
A stratification approach using logit-based models for confounder adjustment in the study of continuous outcomes. 38
29278142 2019
47
Body mass index, mammographic density, and breast cancer risk by estrogen receptor subtype. 38
30944014 2019
48
Using an automated measure of breast density to explore the association between ethnicity and mammographic density in Australian women. 38
30623584 2019
49
[THE EFFECTS OF HORMONAL REPLACEMENT THERAPY (HRT) ON MAMMOGRAPHIC BREAST DENSITY AND ABNORMAL MAMMOGRAMS PROMPTING FURTHER INVESTIGATION]. 38
31032556 2019
50
Preliminary investigation of mammographic density among women in Riyadh: association with breast cancer risk factors and implications for screening practices. 38
30639525 2019

Variations for Mammographic Density

Expression for Mammographic Density

Search GEO for disease gene expression data for Mammographic Density.

Pathways for Mammographic Density

Pathways related to Mammographic Density according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.89 CYP1B1 CYP1A1 CYP19A1 CYP17A1 COMT
2
Show member pathways
11.69 PRL PGR ESR1
3
Show member pathways
11.65 CYP1B1 CYP1A1 CYP19A1
4
Show member pathways
11.58 HSD17B1 CYP19A1 CYP17A1
5
Show member pathways
11.39 HSD17B1 CYP1A1 CYP19A1 CYP17A1 COMT
6 11.26 ESR1 CYP1B1 CYP1A1
7
Show member pathways
11.25 HSD17B1 CYP1B1 CYP1A1 CYP19A1 CYP17A1 COMT
8
Show member pathways
11.17 CYP1B1 CYP1A1
9 11.14 CYP1B1 CYP1A1
10
Show member pathways
11.09 HSD17B1 CYP1B1 CYP1A1 CYP19A1 COMT
11
Show member pathways
11.08 CYP1B1 CYP1A1
12 11.06 PGR CYP19A1
13
Show member pathways
10.85 HSD17B1 CYP17A1
14 10.83 IGFBP3 IGF1
15 10.79 IGF1 HSD17B1 CYP1B1 CYP1A1 CYP19A1 CYP17A1
16 10.66 ESR1 CYP1B1 CYP1A1
17 10.13 HSD17B1 CYP19A1
18 10.1 HSD17B1 ESR1 CYP19A1

GO Terms for Mammographic Density

Cellular components related to Mammographic Density according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 insulin-like growth factor ternary complex GO:0042567 8.96 IGFBP3 IGF1
2 insulin-like growth factor binding protein complex GO:0016942 8.62 IGFBP3 IGF1

Biological processes related to Mammographic Density according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 oxidation-reduction process GO:0055114 9.8 HSD17B1 CYP1B1 CYP1A1 CYP19A1 CYP17A1
2 cellular protein metabolic process GO:0044267 9.77 PRL IGFBP3 IGF1
3 steroid metabolic process GO:0008202 9.67 CYP1B1 CYP1A1 CYP17A1
4 negative regulation of smooth muscle cell proliferation GO:0048662 9.59 IGFBP3 COMT
5 regulation of multicellular organism growth GO:0040014 9.58 PRL IGF1
6 positive regulation of JAK-STAT cascade GO:0046427 9.58 PRL CYP1B1
7 response to lipopolysaccharide GO:0032496 9.57 CYP1A1 COMT
8 epoxygenase P450 pathway GO:0019373 9.56 CYP1B1 CYP1A1
9 uterus development GO:0060065 9.55 ESR1 CYP19A1
10 developmental process GO:0032502 9.54 CYP1A1 COMT
11 androgen metabolic process GO:0008209 9.52 ESR1 CYP19A1
12 response to organic cyclic compound GO:0014070 9.51 CYP1A1 COMT
13 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.48 IGFBP3 IGF1
14 estrogen biosynthetic process GO:0006703 9.46 HSD17B1 CYP19A1
15 omega-hydroxylase P450 pathway GO:0097267 9.43 CYP1B1 CYP1A1
16 steroid biosynthetic process GO:0006694 9.43 HSD17B1 CYP19A1 CYP17A1
17 toxin metabolic process GO:0009404 9.37 CYP1B1 CYP1A1
18 mammary gland development GO:0030879 9.33 PRL PGR CYP19A1
19 testosterone biosynthetic process GO:0061370 9.32 HSD17B1 CYP19A1
20 sterol metabolic process GO:0016125 8.96 CYP1B1 CYP19A1
21 estrogen metabolic process GO:0008210 8.8 HSD17B1 CYP1B1 COMT

Molecular functions related to Mammographic Density according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.85 HSD17B1 CYP1B1 CYP1A1 CYP19A1 CYP17A1
2 iron ion binding GO:0005506 9.71 CYP1B1 CYP1A1 CYP19A1 CYP17A1
3 heme binding GO:0020037 9.67 CYP1B1 CYP1A1 CYP19A1 CYP17A1
4 monooxygenase activity GO:0004497 9.61 CYP1B1 CYP1A1 CYP19A1
5 steroid binding GO:0005496 9.5 PGR HSD17B1 ESR1
6 steroid hydroxylase activity GO:0008395 9.49 CYP1A1 CYP19A1
7 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen GO:0016712 9.43 CYP1B1 CYP1A1 CYP19A1
8 aromatase activity GO:0070330 9.33 CYP1B1 CYP1A1 CYP19A1
9 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.26 CYP1B1 CYP1A1 CYP19A1 CYP17A1
10 oxygen binding GO:0019825 8.92 CYP1B1 CYP1A1 CYP19A1 CYP17A1
11 metal ion binding GO:0046872 10.08 PGR IGFBP3 ESR1 CYP1B1 CYP1A1 CYP19A1

Sources for Mammographic Density

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....